

SKYEPHARMA PLC
Form 6-K
March 03, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

SkyePharma PLC

Clarification of Financial Position

LONDON, UK, 3 March 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) wishes to clarify its financial position regarding the NAV group in the media today.

Under the UK Listing Rules a company is required to report if there is a material change in its financial position. There has been no material change in SkyePharma's financial condition since the working capital statement in the last financial statement.

Yesterday the NAV group issued a document and SkyePharma responded to all its claims proving that the NAV group's financial governance are completely without foundation. However, verbally the NAV group has made outrageous claims about SkyePharma's financial position.

No mention of the alleged cash problem was included in the NAV group's written release. This is a deliberate tactic by this small collection of shareholders who are using which continue to destroy value in SkyePharma. The damage these slurs are causing.

Jerry Karabelas said:

"There is no cash problem.

"The behaviour of the NAV group is disgraceful. Having failed to make their innuendos over the years, they have now spread rumours which are simply untrue.

"The time has come for other shareholders to stand up for SkyePharma before the NAV group do any more damage."

For further information please contact:

SkyePharma PLC	+44 207 491 1777
Frank Condella, Chief Executive Officer	
Peter Laing, Director of Corporate Communications	+44 207 491 5124
Sandra Haughton, US Investor Relations	+1 212 753 5780
Buchanan Communications	+44 207 466 5000
Tim Anderson / Mark Court	

Notes for editors:

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information visit www.skyepharma.com.

Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbor provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations expressed in these statements are reasonable, it can give no assurance that these expectations will materialize. Because of a number of risks and uncertainties, actual results may vary significantly from those expressed or implied in these statements. These risks include, but are not limited to, risks related to the development of new products, risks related to obtaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to commercialize its products on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to maintain or expand market share in the face of changes in customer requirements, competition and other factors, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership

Edgar Filing: SKYEPHARMA PLC - Form 6-K

risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to make a forward-looking statement to reflect events or circumstances after the date of this release.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: March 3, 2006